Abstract| Volume 16, ISSUE 4, SUPPLEMENT , S28, April 2014

Generation and qualification of a GMP compliant master cell stock of CAR expressing ErbB2-specific NK-92 cells for clinical trials

      The continuously growing NK-92 cell line is highly cytotoxic against a broad spectrum of tumor targets and has completed phase I clinical trials in humans. To further improve the anticancer activity towards ErbB2 expressing cancer cells NK-92 cells from an FDA-licensed master cell stock (MCS) were transduced under GMP-compliant conditions with an ErbB2-specific humanized CAR construct by lentiviral gene transfer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect